121 related articles for article (PubMed ID: 31462708)
1. ALK
Xu BS; Chen HY; Que Y; Xiao W; Zeng MS; Zhang X
Oncogene; 2020 Jan; 39(1):151-163. PubMed ID: 31462708
[TBL] [Abstract][Full Text] [Related]
2. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.
Wiesner T; Lee W; Obenauf AC; Ran L; Murali R; Zhang QF; Wong EW; Hu W; Scott SN; Shah RH; Landa I; Button J; Lailler N; Sboner A; Gao D; Murphy DA; Cao Z; Shukla S; Hollmann TJ; Wang L; Borsu L; Merghoub T; Schwartz GK; Postow MA; Ariyan CE; Fagin JA; Zheng D; Ladanyi M; Busam KJ; Berger MF; Chen Y; Chi P
Nature; 2015 Oct; 526(7573):453-7. PubMed ID: 26444240
[TBL] [Abstract][Full Text] [Related]
3. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
4. CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics.
Feng BH; Liu AG; Gu WG; Deng L; Cheng XG; Tong TJ; Zhang HZ
Oncol Rep; 2013 Aug; 30(2):815-23. PubMed ID: 23708735
[TBL] [Abstract][Full Text] [Related]
5. Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma.
Lohberger B; Rinner B; Stuendl N; Absenger M; Liegl-Atzwanger B; Walzer SM; Windhager R; Leithner A
PLoS One; 2012; 7(8):e43664. PubMed ID: 22928012
[TBL] [Abstract][Full Text] [Related]
6. Identification and Characterization of Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma Using the SORE6 Reporter.
Li J; Haque M; Shang C; Hassan B; Liu D; Chen W; Lai R
Curr Issues Mol Biol; 2021 Jul; 43(2):543-557. PubMed ID: 34287231
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma.
Wu C; Gupta N; Huang YH; Zhang HF; Alshareef A; Chow A; Lai R
BMC Cancer; 2018 Apr; 18(1):361. PubMed ID: 29609590
[TBL] [Abstract][Full Text] [Related]
8. Correlation of novel ALK
Shah KK; Neff JL; Erickson LA; Jackson RA; Jenkins SM; Mansfield AS; Moser JC; Harris AL; Copland JA; Halling KC; Flotte TJ
Histopathology; 2020 Oct; 77(4):601-610. PubMed ID: 32564377
[TBL] [Abstract][Full Text] [Related]
9. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
[TBL] [Abstract][Full Text] [Related]
10. The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor.
Ouyang L; Yan B; Liu Y; Mao C; Wang M; Liu N; Wang Z; Liu S; Shi Y; Chen L; Wang X; Cheng Y; Cao Y; Xiao D; Zhang L; Liu S; Tao Y
Signal Transduct Target Ther; 2020 Jun; 5(1):78. PubMed ID: 32546741
[TBL] [Abstract][Full Text] [Related]
11. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.
Zhao D; Pan C; Sun J; Gilbert C; Drews-Elger K; Azzam DJ; Picon-Ruiz M; Kim M; Ullmer W; El-Ashry D; Creighton CJ; Slingerland JM
Oncogene; 2015 Jun; 34(24):3107-19. PubMed ID: 25151964
[TBL] [Abstract][Full Text] [Related]
12. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
13. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
14. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions.
Sasaki N; Ishiwata T; Hasegawa F; Michishita M; Kawai H; Matsuda Y; Arai T; Ishikawa N; Aida J; Takubo K; Toyoda M
Cancer Sci; 2018 Apr; 109(4):1135-1146. PubMed ID: 29444383
[TBL] [Abstract][Full Text] [Related]
15. Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes.
Hu J; Li J; Yue X; Wang J; Liu J; Sun L; Kong D
Oncotarget; 2017 Apr; 8(17):28463-28470. PubMed ID: 28212529
[TBL] [Abstract][Full Text] [Related]
16. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
Hoareau-Aveilla C; Quelen C; Congras A; Caillet N; Labourdette D; Dozier C; Brousset P; Lamant L; Meggetto F
Haematologica; 2019 Feb; 104(2):347-359. PubMed ID: 30262555
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma.
Tornin J; Martinez-Cruzado L; Santos L; Rodriguez A; Núñez LE; Oro P; Hermosilla MA; Allonca E; Fernández-García MT; Astudillo A; Suarez C; Morís F; Rodriguez R
Oncotarget; 2016 May; 7(21):30935-50. PubMed ID: 27105533
[TBL] [Abstract][Full Text] [Related]
18. cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.
Berberich A; Schmitt LM; Pusch S; Hielscher T; Rübmann P; Hucke N; Latzer P; Heßling B; Lemke D; Kessler T; Platten M; Wick W
J Neurooncol; 2020 Jan; 146(1):9-23. PubMed ID: 31776900
[TBL] [Abstract][Full Text] [Related]
19. Bile acid: a potential inducer of colon cancer stem cells.
Farhana L; Nangia-Makker P; Arbit E; Shango K; Sarkar S; Mahmud H; Hadden T; Yu Y; Majumdar AP
Stem Cell Res Ther; 2016 Dec; 7(1):181. PubMed ID: 27908290
[TBL] [Abstract][Full Text] [Related]
20. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
